CLINICAL TRIALS PROFILE FOR FARYDAK

All Clinical Trials for Farydak

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Beth Israel Deaconess Medical Center	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Brigham and Women's Hospital	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Genentech, Inc.	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Massachusetts General Hospital	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Northwestern University	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	Novartis	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
NCT00859222 ↗	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Completed	University of Virginia	Phase 1/Phase 2	2009-03-01	The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.

Clinical Trial Conditions for Farydak

Condition Name

Condition Name for Farydak
Intervention	Trials
Recurrent Plasma Cell Myeloma	4
Refractory Plasma Cell Myeloma	4
Diffuse Intrinsic Pontine Glioma	2
Multiple Myeloma	2

Condition MeSH

Condition MeSH for Farydak
Intervention	Trials
Neoplasms, Plasma Cell	5
Multiple Myeloma	5
Glioma	3
Graft vs Host Disease	2

Clinical Trial Locations for Farydak

Trials by Country

Trials by Country for Farydak
Location	Trials
United States	24
Italy	11
Australia	5
Germany	4
South Africa	3

Trials by US State

Trials by US State for Farydak
Location	Trials
Texas	4
Massachusetts	3
Ohio	2
California	2
Florida	2

Clinical Trial Progress for Farydak

Clinical Trial Phase

Clinical Trial Phase for Farydak
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Farydak
Clinical Trial Phase	Trials
Recruiting	5
Active, not recruiting	2
Terminated	2

Clinical Trial Sponsors for Farydak

Sponsor Name

Sponsor Name for Farydak
Sponsor	Trials
Novartis	4
National Cancer Institute (NCI)	4
Novartis Pharmaceuticals	3

Sponsor Type

Sponsor Type for Farydak
Sponsor	Trials
Other	18
Industry	13
NIH	4